Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
7.59
-0.29 (-3.68%)
At close: Mar 28, 2025, 4:00 PM
7.47
-0.12 (-1.58%)
After-hours: Mar 28, 2025, 7:22 PM EDT

Rocket Pharmaceuticals Stock Forecast

RCKT's stock price has decreased by -72.15% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 10 analysts with 12-month price forecasts for Rocket Pharmaceuticals stock have an average target of 44.1, with a low estimate of 15 and a high estimate of 65. The average target predicts an increase of 481.03% from the current stock price of 7.59.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $15 $44.1 $50 $65
Change +97.63% +481.03% +558.76% +756.39%

Analyst Ratings

The average analyst rating for Rocket Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Oct '24Nov '24Dec '24Jan '25Feb '25Mar '25
Strong Buy 445554
Buy 455545
Hold 111111
Sell 000000
Strong Sell 000000
Total 91011111010

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
BMO Capital
BMO Capital
Buy
Initiates
$50
Buy Initiates $50 +558.76% Mar 12, 2025
Scotiabank
Scotiabank
Buy
Maintains
$51$52
Buy Maintains $51$52 +585.11% Mar 3, 2025
Goldman Sachs
Goldman Sachs
Hold
Maintains
$29$15
Hold Maintains $29$15 +97.63% Mar 3, 2025
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$39$36
Strong Buy Maintains $39$36 +374.31% Mar 3, 2025
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$62$54
Strong Buy Maintains $62$54 +611.46% Feb 28, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
from 803.41M
Revenue Next Year
n/a
EPS This Year
-2.42
from -2.73
EPS Next Year
-1.64
from -2.42
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027 FY 2028 FY 2029
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027 Dec 31, 2028 Dec 31, 2029
Revenue
46.19M188.22M491.55M632.42M803.41M
Revenue Growth
-307.50%161.16%28.66%27.04%---
EPS
-2.52-2.67-3.26-2.92-2.73-2.42-1.640.18
EPS Growth
--------
Forward PE
-------42.33
No. Analysts -----191912
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 233.1M 562.9M 1.3B
Avg 46.2M 188.2M 491.6M
Low n/a 7.3M 18.0M

Revenue Growth

Revenue Growth 20252026202720282029
High
-71.0%
1,118.8%
568.9%
Avg
-94.3%
307.5%
161.2%
Low -
-84.2%
-90.4%

EPS Forecast

EPS 20252026202720282029
High -1.44 -0.04 2.32
Avg -2.42 -1.64 0.18
Low -3.30 -2.46 -1.78

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.